Literature DB >> 17907152

Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.

John M Chirgwin1, Theresa A Guise.   

Abstract

Several common cancers often metastasize to the skeleton in advanced disease. Bone metastases are incurable and cause protracted, severe symptoms. Growth of tumor in bone is driven by a vicious cycle: tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines. The bone-derived factors fuel the vicious cycle by acting back on the tumor cells. The vicious cycle offers novel targets for the treatment of advanced cancers. Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor-secreted factors. Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor-beta. Animal models show that these approaches, especially combination treatments, can reduce tumor burden. The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenvironment and not the tumor cells themselves. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17907152     DOI: 10.1002/jcb.21556

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  13 in total

1.  Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.

Authors:  Jinlu Dai; Yi Lu; Chunyan Yu; Jill M Keller; Atsushi Mizokami; Jian Zhang; Evan T Keller
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 2.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

Review 3.  Gene targeting to the stroma of the prostate and bone.

Authors:  Roger S Jackson; Omar E Franco; Neil A Bhowmick
Journal:  Differentiation       Date:  2008-05-20       Impact factor: 3.880

4.  Breast cancer bone metastases: denosumab or zoledronic acid?

Authors:  Gabri van der Pluijm
Journal:  Nat Rev Endocrinol       Date:  2011-03       Impact factor: 43.330

5.  Automated detection of sclerotic metastases in the thoracolumbar spine at CT.

Authors:  Joseph E Burns; Jianhua Yao; Tatjana S Wiese; Hector E Muñoz; Elizabeth C Jones; Ronald M Summers
Journal:  Radiology       Date:  2013-02-28       Impact factor: 11.105

Review 6.  The multifaceted actions of PTHrP in skeletal metastasis.

Authors:  Fabiana N Soki; Serk In Park; Laurie K McCauley
Journal:  Future Oncol       Date:  2012-07       Impact factor: 3.404

7.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

8.  The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.

Authors:  Daniel A Rauch; Michelle A Hurchla; John C Harding; Hongju Deng; Lauren K Shea; Mark C Eagleton; Stefan Niewiesk; Michael D Lairmore; David Piwnica-Worms; Thomas J Rosol; Jason D Weber; Lee Ratner; Katherine N Weilbaecher
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

9.  Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.

Authors:  Daniel Mendoza-Villanueva; Leo Zeef; Paul Shore
Journal:  Breast Cancer Res       Date:  2011-10-27       Impact factor: 6.466

10.  Probing the interaction forces of prostate cancer cells with collagen I and bone marrow derived stem cells on the single cell level.

Authors:  Ediz Sariisik; Denitsa Docheva; Daniela Padula; Cvetan Popov; Jan Opfer; Matthias Schieker; Hauke Clausen-Schaumann; Martin Benoit
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.